Recruiting — limited enrollment
What is being offered: Official study page updated 2026-08-15. Exploratory multicenter IIT for canine malignant tumors using fresh tumor plus paired adjacent normal tissue for >=50G RNA sequencing, neoantigen selection and personalized mRNA-LNP immunotherapy. T-cell lymphoma and brain tumors are explicitly excluded and therefore are not mapped to this record. Requires histologic or cytologic confirmation, age >=2 years, generally weight >=5 kg (smaller dogs may be individually assessed), fresh tumor and paired normal tissue obtainable at surgery; dogs already operated may still be considered if tissue was correctly frozen. Also requires adequate performance status/labs and successful LNP tolerance testing. Excludes recent chemotherapy/radiation/high-dose corticosteroids within 2 weeks, severe infection/autoimmune disease/immunodeficiency, pregnancy/lactation, and expected survival <6 months. Owners pay some sampling/freezing/sequencing costs; personalized mRNA design/manufacture is funded by PETcura.
Who may qualify: Confirmed cancer diagnosis required; Min age years: 2
May not qualify if: Tcell lymphoma lineage
Costs / coverage: 🟡 Partially funded. PETcura fully funds design and manufacture of the personalized mRNA product; owners pay part of the sampling, specimen-storage and sequencing service costs. The project provides the detailed amount during enrollment assessment.
Contact: WeChat: petcura; project team matches eligible owners with a participating veterinarian/hospital.
Enrollment area
- Beijing, 2 hospitals, China
- Shanghai, 1 hospital, China
- Guangzhou, 1 hospital, China
- Hangzhou, 2 hospitals, China
- Nanjing, 2 hospitals, China
- Shenzhen, 1 hospital, China
- Shenyang, 1 hospital, China
- Chengdu, 1 hospital, China
- Chongqing, 1 hospital, China
The public study listing names a partner-hospital network rather than a specific hospital. Confirm the assigned hospital with the study team.